| Business Summary | | Flamel
Technologies
S.A.
is
a
biopharmaceutical
company
principally
engaged
in
the
development
of
two
polymer-based
delivery
technologies
for
medical
applications.
Flamel's
Medusa
nano-encapsulation
technology
is
designed
to
deliver
therapeutic
proteins.
Micropump
is
a
controlled-release
technology
for
the
oral
administration
of
small
molecule
drugs.
Flamel's
expertise
in
polymer
science
has
also
been
instrumental
in
the
development
of
a
photochromic
eyeglass
lens
product
now
marketed
by
Corning
Inc.
Additionally,
Flamel
has
developed
new
herbicide
delivery
systems
now
being
tested
by
Monsanto
and
has
patented
a
biomaterial,
ColCys. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Flamel
Technologies
S.A.
is
engaged
in
the
development
and
commercialization
of
controlled-release
therapeutic
products
based
on
its
proprietary
polymer-based
technology.
For
the
six
months
ended
6/30/01,
revenues
rose
13%
to
$5.9
million.
Net
loss
before
accounting
change
fell
19%
to
$2.1
million.
Revenues
reflect
the
progress
made
by
Novo
Nordisk
regarding
a
key
development.
Lower
loss
also
reflects
decreased
costs
of
goods
sold. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
2,433;
after
tax
earnings
were
-1,360. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Gerard Soula | Pres,
CEO, Director of R&D | Stephen Willard | CFO,
Exec. VP, Gen. Counsel | Michael Myers, Ph.D. | Exec.
VP of Sales, Marketing and Bus. Devel. | Emanuelle Bardet | VP
and Chief Pharmacist | Rafael Jorda | VP
of Manufacturing |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|